Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study.
Stintzing S, Klein-Scory S, Fischer von Weikersthal L, Fuchs M, Kaiser F, Heinrich K, Modest DP, Hofheinz RD, Decker T, Gerger A, Angermeier S, Rumpold H, Dickhut A, Öhler L, Gruenberger B, Niedersuess-Beke D, Sandmann M, Winder T, Trojan J, Prager G, Held S, Kumbrink J, Schmiegel W, Baraniskin A, Heinemann V. Stintzing S, et al. Among authors: modest dp. J Clin Oncol. 2025 Apr 20;43(12):1463-1473. doi: 10.1200/JCO.24.01174. Epub 2025 Feb 4. J Clin Oncol. 2025. PMID: 39903881 Clinical Trial.
[Significance of Mesenchymal Stem Cells in Gastrointestinal Disorders].
Gamba S, Zhao Y, Zhao L, Wang Y, Schwarz B, Primo S, Jauch KW, Nelson PJ, Modest DP, Nieß H, Bruns C. Gamba S, et al. Among authors: modest dp. Zentralbl Chir. 2015 Jun;140(3):294-303. doi: 10.1055/s-0032-1328561. Epub 2013 Jul 8. Zentralbl Chir. 2015. PMID: 23836276 Review. German.
Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer.
Giessen C, Stintzing S, Laubender RP, Ankerst DP, Schulz C, Moosmann N, Modest DP, Schalhorn A, von Weikersthal LF, Heinemann V. Giessen C, et al. Among authors: modest dp. Clin Colorectal Cancer. 2011 Dec;10(4):317-24. doi: 10.1016/j.clcc.2011.03.027. Epub 2011 May 12. Clin Colorectal Cancer. 2011. PMID: 21729676 Clinical Trial.
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
Giessen C, von Weikersthal LF, Hinke A, Stintzing S, Kullmann F, Vehling-Kaiser U, Mayerle J, Bangerter M, Denzlinger C, Sieber M, Teschendorf C, Freiberg-Richter J, Schulz C, Modest DP, Moosmann N, Aubele P, Heinemann V. Giessen C, et al. Among authors: modest dp. BMC Cancer. 2011 Aug 23;11:367. doi: 10.1186/1471-2407-11-367. BMC Cancer. 2011. PMID: 21861888 Free PMC article. Clinical Trial.
[Colon cancer: adjuvant chemotherapy and aftercare].
Heinemann V, Giessen C, Modest D, Moosmann N, Stintzing S. Heinemann V, et al. MMW Fortschr Med. 2011 Sep 1;153(35):34-6. MMW Fortschr Med. 2011. PMID: 21916303 German. No abstract available.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.
Stintzing S, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, Jäger E, Heintges T, Stoll C, Giessen C, Modest DP, Neumann J, Jung A, Kirchner T, Scheithauer W, Heinemann V. Stintzing S, et al. Among authors: modest dp. Ann Oncol. 2012 Jul;23(7):1693-9. doi: 10.1093/annonc/mdr571. Epub 2012 Jan 4. Ann Oncol. 2012. PMID: 22219013 Free article. Clinical Trial.
Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group.
Stintzing S, Kapaun C, Laubender RP, Jung A, Neumann J, Modest DP, Giessen C, Moosmann N, Wollenberg A, Kirchner T, Heinemann V. Stintzing S, et al. Among authors: modest dp. Int J Cancer. 2013 Jan 1;132(1):236-45. doi: 10.1002/ijc.27654. Epub 2012 Jun 26. Int J Cancer. 2013. PMID: 22644776 Clinical Trial.
168 results